Price$16.17-0.27 (-1.64%)
01:30 PM07:45 PM
News · 26 weeks81+57%
2026-01-182026-07-12
Mix3190d
- Insider10(32%)
- Other9(29%)
- SEC Filings8(26%)
- Earnings4(13%)
Latest news
25 items- PRHercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference CallHercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2026 financial results conference call for Thursday, July 30, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section of
- INSIDERChief Operating Officer Follmann Christian covered exercise/tax liability with 2,798 shares, decreasing direct ownership by 2% to 144,539 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- INSIDERPresident Meyer Seth H covered exercise/tax liability with 6,469 shares, decreasing direct ownership by 1% to 435,605 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- INSIDERChief Executive Officer Bluestein Scott covered exercise/tax liability with 20,393 shares, decreasing direct ownership by 0.82% to 2,475,593 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- INSIDERChief Legal Officer & CCO Botelho Kiersten Zaza covered exercise/tax liability with 1,974 shares, decreasing direct ownership by 2% to 89,388 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- PR4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalEMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE:HTGC) ("Hercules") for up to $200 million. "Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital
- SECSEC Form S-8 filed by Hercules Capital Inc.S-8 - Hercules Capital, Inc. (0001280784) (Filer)
- INSIDERDirector Badavas Robert P was granted 3,873 shares, increasing direct ownership by 76% to 8,943 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- INSIDERDirector Badavas Robert P was granted 3,873 shares, increasing direct ownership by 76% to 8,943 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- INSIDERDirector Badavas Robert P was granted 3,873 shares, increasing direct ownership by 76% to 8,943 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- INSIDERDirector Badavas Robert P was granted 3,873 shares, increasing direct ownership by 76% to 8,943 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- SECHercules Capital Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Hercules Capital, Inc. (0001280784) (Filer)
- PRBehavox Raises $175 Million from HPS Investment Partners, Part of BlackRock, to Accelerate Global GrowthInvestment follows a year of strong commercial momentum, with Behavox growing its customer base 86% to more than 100 major financial institutions across five continents Behavox, the AI-native controls platform for global banks, asset managers, hedge funds, and commodity firms, today announced a $175 million preferred equity investment from investment funds and accounts managed by HPS Investment Partners, a leading global credit investment firm and a part of BlackRock ("HPS"). The completed investment positions Behavox to accelerate global growth, expand its Unified Controls Platform, and pursue disciplined M&A. With this investment, HPS joins a roster of leading institutional investors
- PRDyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction further strengthens the company's balan
- INSIDERChief Financial Officer Meyer Seth H covered exercise/tax liability with 5 shares, decreasing direct ownership by 0.00% to 442,074 units (SEC Form 4)4 - Hercules Capital, Inc. (0001280784) (Issuer)
- PRBeren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C-- $135 million equity financing with participation from leading specialist investors, corporate investors, and long-term growth partners, including Wellington Partners, JIC Venture Growth Investments (JIC VGI), Founders Fund, Narya Capital, Eisai Co., Ltd., and other select institutional investors -- Up to $165 million in flexible, non-dilutive capital, including $110 million senior-secured debt facility and $55 million of royalty financing with Hercules Capital, Inc. -- Financing will support investments in commercial readiness activities for adrabetadex ahead of its November 17, 2026, Prescription Drug User Fee Act (PDUFA) target action date. This will include the development of a long-t
- PRPerk Secures $300 Million Credit Facility to Accelerate Global Growth of Its AI-Native PlatformThe $300m facility backed by top-tier lenders reflects strong conviction in Perk's vision to build a leading AI-native platform for travel and spend management Perk enters its next phase of growth on the back of a 48% revenue growth in 2025, best-in-category gross margins, and a platform built for global scale The new credit facility upsizes and replaces Perk's prior facility on materially improved terms, while increasing available capital to further strengthen an already strong balance sheet Perk (formerly TravelPerk), the AI-native travel and spend management platform, today announced the close of a $300 million private credit facility led by Neuberger Speciality Finance, alongs
- INSIDERNew insider Olson Andrew claimed ownership of 30,386 shares (SEC Form 3)3 - Hercules Capital, Inc. (0001280784) (Issuer)
- PRHercules Capital Announces Date of 2026 Annual Meeting of StockholdersHercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), will conduct its 2026 Annual Meeting of Stockholders by virtual meeting on Thursday, June 18, 2026 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 23, 2026 and mailed to stockholders of record as of April 9, 2026. 2026 Annual Meeting of Stockholders June 18, 2026 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2026 Matters to be voted on include: 1) election of an independent director, 2) an advisory vote to approve the Company's named executive officer compensation, 3) an advisory vote on the frequency of the adv
- SECHercules Capital Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Hercules Capital, Inc. (0001280784) (Filer)
- SECSEC Form 10-Q filed by Hercules Capital Inc.10-Q - Hercules Capital, Inc. (0001280784) (Filer)
- PRHercules Capital Reports First Quarter 2026 Financial ResultsRecord Q1 2026 Total New Debt and Equity Commitments of $1.81 Billion, an Increase of 77.8% Year-over-Year Q1 2026 Total Fundings of $706.4 Million, an Increase of 31.0% Year-over-Year Record Q1 2026 Total Investment Income of $141.5 Million, an Increase of 18.4% Year-over-Year Q1 2026 Net Investment Income "NII" of $88.1 Million, an Increase of 13.8% Year-over-Year Q1 2026 NII of $0.48 per Share provides 120% Coverage of the Base Cash Distribution Closed Institutional Notes Offering of $300.0 Million of 5.350% Unsecured Notes due 2029 Conservative Balance Sheet Management with Net GAAP Leverage of 113.5% and Net Regulatory Leverage of 97.8%(1) Inclusive of the Adviser Funds A
- SECSEC Form DEFA14A filed by Hercules Capital Inc.DEFA14A - Hercules Capital, Inc. (0001280784) (Filer)
- SECHercules Capital Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Hercules Capital, Inc. (0001280784) (Filer)
- PRLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalTHE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE:HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones. "Operational excellence, financial discipline and financial flexibility are key pillars of our corporate strategy for long-term growth," said Scott Coiante, Lexicon's
HTGC FAQ
8 questionsWhat does Hercules Capital Inc. do?
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and...Where does HTGC stock trade?
Hercules Capital Inc. (HTGC) is listed on NYSE.What sector and industry is HTGC in?
Hercules Capital Inc. operates in the Finance sector, Investment Managers industry.When did Hercules Capital Inc. go public?
Hercules Capital Inc. (HTGC) completed its IPO in 2012.Does HTGC pay a dividend?
HTGC's most recent ex-dividend date was 2026-05-14 with a cash dividend of $0.40 per share. No future ex-date is on file yet.What are analysts saying about HTGC?
Hercules Capital Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $1750.00 price target on 2026-02-13. Recent price targets range from $1600.00 to $2150.00.What companies are similar to HTGC?
Notable peers in the same industry include BX (Blackstone Inc.), KKR (KKR & Co. Inc.), APO (Apollo Global Management Inc. (New)), AMP (Ameriprise Financial Inc.), ARES (Ares Management Corporation). Compare HTGC side-by-side with any of them on Quantisnow.How can I track HTGC on Quantisnow?
Quantisnow aggregates Hercules Capital Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HTGC to receive live email and push alerts on every new disclosure.